Changes in Beneficial Ownership · 4
Invivyd, Inc.
IVVDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-31
- Issuer
- Invivyd, Inc.
- Issuer CIK
- 0001832038
- Trading symbol
- IVVD
Reporting owner 1
- Name
- Sheffield Ian
- Reporting owner CIK
- 0001594410
- Relationship
- Director
- Address
- C/O INVIVYD, INC., 205 CHURCH STREET, NEW HAVEN, CT, 06510
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 0.9549 | 2026-08-31 | A · Form 4 | 100,000 | A | 0 | [F1] | 2036-08-30 | Common Stock | 100,000 | 100,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- This option was granted on August 31, 2026 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the total shares subject to the grant vesting in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.↩ 1
Signature 1
- Signed
- /s/ Jill Andersen attorney-in-fact for Ian Sheffield
- Date
- 2026-09-02
Company context
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.